Gu, Y., Qiu, T., Mingjie, L., Dong, Y. (2026). Fruquintinib in combination with camrelizumab, paclitaxel liposome, and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from a single-arm, phase II study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e16070